For stage IV NSCLC patients with a sensitizing EGFR Ex19del/L858R mutation, gefitinib, erlotinib, or icotinib is recommended as the best first-line treatment in the clinic. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.